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Abstract
A current controversy is whether patients with sepsis progress to an immunosuppressed state. We hypothesized that
reactivation of latent viruses occurred with prolonged sepsis thereby providing evidence of clinically-relevant
immunosuppression and potentially providing a means to serially-monitor patients’ immune status. Secondly, if viral
loads are markedly elevated, they may contribute to morbidity and mortality. This study determined if reactivation of
herpesviruses, polyomaviruses, and the anellovirus TTV occurred in sepsis and correlated with severity. Serial whole blood
and plasma samples from 560 critically-ill septic, 161 critically-ill non-septic, and 164 healthy age-matched patients were
analyzed by quantitative-polymerase-chain-reaction for cytomegalovirus (CMV), Epstein-Barr (EBV), herpes-simplex (HSV),
human herpes virus-6 (HHV-6), and TTV. Polyomaviruses BK and JC were quantitated in urine. Detectable virus was analyzed
with respect to secondary fungal and opportunistic bacterial infections, ICU duration, severity of illness, and survival.
Patients with protracted sepsis had markedly increased frequency of detectable virus. Cumulative viral DNA detection rates
in blood were: CMV (24.2%), EBV (53.2%), HSV (14.1%), HHV-6 (10.4%), and TTV (77.5%). 42.7% of septic patients had
presence of two or more viruses. The 50% detection rate for herpesviruses was 5–8 days after sepsis onset. A small
subgroup of septic patients had markedly elevated viral loads (.104–106 DNA copies/ml blood) for CMV, EBV, and HSV.
Excluding TTV, DNAemia was uncommon in critically-ill non-septic patients and in age-matched healthy controls. Compared
to septic patients without DNAemia, septic patients with viremia had increased fungal and opportunistic bacterial
infections. Patients with detectable CMV in plasma had higher 90-day mortality compared to CMV-negative patients; p,
0.05. Reactivation of latent viruses is common with prolonged sepsis, with frequencies similar to those occurring in
transplant patients on immunosuppressive therapy and consistent with development of an immunosuppressive state.
Whether reactivated latent viruses contribute to morbidity and mortality in sepsis remains unknown.
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Introduction
Sepsis is the host’s non-resolving inflammatory response to
infection that leads to organ dysfunction [1,2]. A current
controversial hypothesis postulates that if sepsis pursues a
protracted course, it progresses from an initial primarily hyper-
inflammatory phase to a predominantly immunosuppressive state
[3–7]. Experimental therapeutic approaches in sepsis have almost
exclusively focused on blocking early inflammation or host-
pathogen interaction and failed [8–10]. Recently, immuno-
adjuvant therapies that boost host immunity, e.g., GM-CSF and
interferon-c, have been successful in small clinical trials thereby
supporting the concept that reversing immunosuppression in sepsis
is a plausible strategy to improve outcome [11,12]. However,
several issues have limited this approach including lack of
consensus that immunosuppression is a clinically important
phenomenon [5,6,13]. Also, difficulty in identifying patients with
impaired immunity as well as determining optimal timing for
administration pose significant challenges to pursuing this
approach [14]. While immuno-adjuvant therapies might improve
sepsis survival if administered during the later immunosuppressive
phase, these agents might worsen outcome if given during the early
hyper-inflammatory phase [4,14]. Thus, a means to distinguish
these two contrasting phases of sepsis is needed not only to verify
the hypothesis that sepsis progresses to an immunosuppressive
state but also to guide use of potential agents which boost
immunity.
Latent viruses such as cytomegalovirus are normally held in
abeyance by cellular and immune surveillance mechanisms which
if impaired, for example by immunosuppressive medications, often
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result in viral reactivation, replication, and virally-mediated tissue
injury [15–20]. Sepsis impairs innate and adaptive immunity by
multiple mechanisms including apoptosis-induced depletion of
immune effector cells and induction of T-cell exhaustion thereby
possibly predisposing to viral reactivation and dissemination [21–
23].
Although viral reactivation has been documented in sepsis,
studies have generally been limited in scope, focusing on CMV
viremia or HSV-1 pneumonitis [15,18,20,24–28]. No compre-
hensive study of the herpes or polyomavirus family has been
conducted in sepsis. Demonstration that widespread reactivation
of latent herpes and polyomavirus occurs in sepsis has several
important implications. First, it would provide strong evidence that
sepsis results in functional immunosuppression and may provide a
means to track patient immunocompetence during the disorder.
Secondly, depending upon the level of viremia, reactivated viruses
may contribute to morbidity and mortality in the disorder. We also
investigated TTV, an anellovirus previously shown to be present in
up to 40–50% of healthy adults [29–33]. Recent studies in patients
with liver and stem cell transplantation, patients with HIV, and
patients with chronic renal failure indicate that the magnitude of
TTV viremia reflects patient immunocompetence and that TTV
viral load is useful as a surrogate marker of the robustness of
immunity [30–33].
Methods: (in addition, see Supporting
Information)
Inclusion criteria
Septic patients. Non-immunocompromised patients treated
in surgical/medical ICUs (2009–2013) were identified prospec-
tively. Sepsis was defined as a microbiologically-proven, clinically-
proven, or suspected infection and presence of systemic inflam-
matory response syndrome [10]. Patients were followed through
hospital discharge or 90 days after sepsis onset. Mortality status at
90 days was available for .95% of study subjects.
Critically-ill non-septic patients (CINS) and healthy-
control patients. Non-septic, non-immunocompromised pa-
tients being treated in surgical/medical ICUs were one compar-
ison group. A second group consisted of age-matched, ambulatory,
pre-operative elective-surgery patients (American Society of
Anesthesiology [ASA] class 1–3).
Exclusion criteria
Patient exclusion criteria included: HIV-1, organ transplanta-
tion, high-dose corticosteroids ($300 mgs/day hydrocortisone) or
other immunosuppressive medications, viral hepatitis, and auto-
immune diseases.
Table 1. Patient Characteristics.
Septic Critically-Ill Non-Septic Healthy Controls
# Patients 560 160 165
Age Median 63 63 64
range[IQR] 52–74 53–76 60–72
Gender (%) Male 305 (55) 81 (51) 81 (49)
Female 255 (45) 79 (49) 84 (51)
Apache II * median 18 5
range[IQR] 15–22 4–7
SOFA** median 7 2
range[IQR] 5–10 1–3
Length of ICU Stay median 11 2
range[IQR] 6–19 2–3
Mortality (%) survived 416 (74) 151 (94)
expired 144 (26) 9 (6)
Admission ICU Diagnosis Trauma 59




Site of Infection Pneumonia 284
Peritonitis 181
Surgical site and wound infection 71
Intravascular catheter infection 14
Urinary tract infection 10
*Apache II, ‘‘Acute Physiology and Chronic Health Evaluation II’’ at ICU admission.
**SOFA, ‘‘Sequential Organ Failure Assessment’’ at ICU admission.
doi:10.1371/journal.pone.0098819.t001
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Blood and Urine Collection
Analyses were performed on residual blood remaining after
clinical hematologic testing was performed (Septic and CINS), or
blood obtained from ambulatory volunteers prior to elective
surgery (Healthy Control). Blood was retrieved daily starting
within 24–72 hrs. of ICU admission. Whole blood and plasma
were stored at 280uC. For detection of BK and JC, urine was
typically obtained twice/week. Quantitative-PCR (qPCR) was
performed 2–3 times/week.
CMV Serologic testing
IgG antibodies to CMV were quantitated by ELISA to identify
individuals with prior CMV exposure.
Sample preparation and viral DNA detection
DNA was extracted using the NucliSens-EasyMag-extractor
(BioMe´rieux) and assayed for viruses by qPCR using protocols
from the Clinical Virology Laboratory at St Louis Children’s
Hospital (except HHV-6 and TTV) and as previously described
[34–39]. Briefly 5 uL of sample was used per reaction, and assays
were performed on either an ABI 7500 Fast system (Applied
Biosystems), or a LightCycler II (Roche). (See Table S1. for details
regarding lower limit of quantitation for each virus and interassay
coefficient-of-variation).
Statistical analysis
Data were analyzed using SAS-Statistical Software. Kaplan-
Meier analyses were used for mortality, ICU length-of-stay, and
secondary infection rates. Chi-square and t-tests were used for
categorical and continuous variables.
Human Studies Human Studies
The study was approved by the Washington University Human
Research Protection Office. Patient consent was obtained for
venipuncture and chart review from pre-operative elective surgery
patients. Oral consent was documented by having the patient sign
the study consent form which was then placed in the patient chart
with an additional copy kept with the research nurse coordinator.
For septic and critically-ill non-septic patients, a waiver of consent
was granted for obtaining excess clinical ‘‘waste’’ laboratory blood
Table 2. Frequency of Viral DNA in Septic and Control Patients.
Virus Septic Critically-Ill Non-Septic Healthy Controls
No. positive{/No. tested (%)
CMV* 86/356 (24.2) 1/89 (1.1) 0/165 (0)
EBV 287/539 (53.2) 18/149 (12.1) 6/165 (3.6)
HSV 76/538 (14.1) 2/150 (1.3) 0/165 (0)
HHV-6 56/539 (10.4) 1/150 (0.7) 7/165 (4.2)
TTV` 179/231 (77.5) 33/55 (63.6) 98/165 (60.1)
JC** 85/238 (35.7) 10/42 (23.8)
BK** 35/237 (14.3) 4/42 (9.5)
Any Virus 432/560 (77.1) 62/161 (38.5) 104/165 (63.0)
.1 Virus 239/560 (42.7) 9/161 (5.6) 9/165 (5.5)
{Except where indicated, No. positive reflects the number of patients who tested positive in either whole blood or plasma or both. No. tested represents the total
number of patients tested.
*Results are from CMV seropositive patients only.
`Tested in plasma only.
**Tested in urine.
doi:10.1371/journal.pone.0098819.t002
Table 3. Frequency of Viral DNA in Blood and Plasma Individually.
Virus Septic Critically-Ill Non-Septic Healthy Controls
Blood Plasma Blood Plasma Blood Plasma
No. positive/No. tested (%)
CMV* 71/345 (20.6) 33/148 (22.3) 1/79 (1.27) 0/29 (0) 0/164 (0) 0/165 (0)
EBV 275/522 (52.7) 75/235 (31.9) 15/127 (11.8) 3/55 (5.45) 5/164 (3.1) 1/165 (0.61)
HSV 65/521 (12.5) 42/235 (17.9) 2/128 (1.56) 0/54 (0) 0/164 (0) 0/164 (0)
HHV-6 35/522 (6.9) 30/235 (12.8) 1/128 (0.78) 0/55 (0) 5/164 (3.1) 6/165 (3.64)
TTV 179/231 (77.5) 35/55 (63.6) 98/165 (60.1)
Any Virus 312/522 (59.8) 204/235 (86.8) 19/128 (14.8) 36/55 (65.5) 10/164 (6.1) 102/165 (61.8)
.1 Virus 106/522 (20.3) 106/522 (20.3) 0/128 (0) 2/55 (3.64) 0/164 (0) 5/165 (3.03)
*Results are from CMV seropositive patients only. No. positive represents the number of patients who tested positive in Blood or in Plasma separately. No. tested
represents the total number of patients tested.
doi:10.1371/journal.pone.0098819.t003
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(that was slated to be discarded) and for review of their relevant
hospital records because these procedures were considered to
represent minimum risk to the patients.
Results
Demographic data
560 septic, 160 CINS, and 165 healthy control patients were
included (Table 1). The 560 septic patients included 31 patients
originally classified as CINS who developed sepsis during their
ICU admission and were transferred into the septic category.
Median duration of ICU stay was 11 days (range 2–127) and 2
days (range 1–12) for septic and CINS patients respectively. The
number of blood samples for septic and CINS patients ranged
from 1–27 (mean 3.1) and 1–2 (mean 1.1) respectively. A single
blood sample was obtained prior to surgery for the healthy control
patients.
Cumulative detection rates and levels of herpes family
viruses
CMV. 70.2% of patients (septic and controls) were CMV
seropositive within 2–4 days of ICU admission, indicative of prior
infection. With one exception, detection of CMV by PCR
occurred only in patients who were CMV seropositive. 24.2% of
septic CMV seropositive patients had CMV detected with
geometric mean (geomean) levels of 6,409 copies/ml whole blood
and 10,896 copies/ml plasma (Figure 1, Tables 2–4). CMV was
detected by PCR in one CINS patient and in no healthy control
patients (Table 2).
Figure 1. Viral levels in septic and control patients. The maximum viral load for each patient is displayed. (Figure 1A) Only data from septic
patients are displayed for CMV, EBV, HSV, and HHV-6 because viral levels in control patients for these viruses were at or below the limit of
quantitation. (Figure 1B) For JC and BK, data are from urine samples of septic and critically-ill non-septic (CINS) patients. (Figure 1C) The maximum viral
load for TTV is displayed for septic, CINS, and healthy control pre-operative elective-surgery (HC) patients. The horizontal line in each graph
represents the geometric mean for the virus level.
doi:10.1371/journal.pone.0098819.g001
Viral Reactivation in Sepsis
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EBV. EBV was detected in blood samples from 53.2% of
septic patients (Tables 2–4). Fifty-two septic patients (18.9%) had
levels $10,000 copies/ml whole blood, a level that is considered
an indication for reducing immunosuppression in solid-organ
transplant recipients at our institution (Figure 1, Table 4). EBV
was detected in 12.1% and 3.6% of CINS and healthy control
patients respectively.
HSV. HSV was detected in 14.1% of septic patients with
geomean equaling 6,144 copies/ml whole blood and 14,342
copies/ml plasma (Tables 2–4). HSV was detected in blood of
1.5% of CINS patients. No healthy control patients had HSV
viremia.
HHV-6. HHV-6 was detected in 10.4% of septic patients
(Tables 2–4). One CINS and 6 (3.3%) healthy control patients
were positive. HHV-6 levels were generally at or below the lower
limit of quantitation of the qPCR assay (3,000 copies/ml blood).
Cumulative detection rate and levels of TTV
TTV was detected in plasma of 77.5% of septic patients with
geomean equaling 64,000 copies/ml (Tables 2–4). TTV was
detected in 63.6% and 60.1% of CINS and healthy control
patients respectively. Geomean TTV levels were 27,000/ml and
21,000/ml in plasma of CINS and healthy control patients
respectively.
Urine BK and JC detection rates and levels
JC was detected in urine of 35.7% of septic patients with
geomean level of 2.36106 copies/ml (Table 2). JC was detected in
23.8% of CINS patients with geomean level of 9.76105 copies/ml.
BK was detected in urine of 14.3% and 9.5% of septic and CINS
patients respectively. BK geomean values were 62,441 copies/ml
and 17,931 copies/ml in septic and CINS patients (Table 4).
Septic patients have multiple viruses with corresponding
high viral titers
Overall, 42.7% of septic patients had two or more viruses
detected during their illness (Table 2). This 42% may underesti-
mate the frequency because not all patients were tested for all
viruses. In a subgroup of 209 patients who were tested for all
viruses, 54.1% were positive for multiple viruses including 27.8%
positive for 2 viruses, 17.2% for 3 viruses, 7.7% for 4 viruses, 3.8%
for 5 viruses, and 0.5% for 6 viruses. We also correlated the impact
of the load of each of the viruses upon the prevalence of other
viruses. In blood samples, the magnitude of the viral load of one
Figure 2. Correlation of viral loads among the individual viruses. Populations were established based upon viral DNA loads; each of these
populations was examined for presence or absence of other viruses. The number of patients in each of the groups is defined as the following:
Negative = no detectable virus, Low = less than lower limit of quantitation (lloq), and High = greater than lloq. The negative, low, and high values
for CMV are N=274, 34, and 37 septic patients, respectively. Negative, low, and high values for EBV are N=247, 213, and 61 septic patients,
respectively; for HSV comparable values are N=465, 38, 18, septic patients, respectively). For HHV-6, Negative =no detectable virus (n = 485 patients),
Positive = detectable virus (n = 36 patients); *p,0.05, **p,0.01, ***p,0.001. These results show that as the blood viral load of one particular virus
increases, there is a corresponding increase in the prevalence of the other herpes family members.
doi:10.1371/journal.pone.0098819.g002
Viral Reactivation in Sepsis
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herpesvirus often correlated with increased prevalence of other
herpesviruses (e.g. it was more common for patients with high
CMV loads to have positive EBV tests than it was for patients who
had low CMV loads or negative CMV tests), Figure 2. This
correlation tended to occur in plasma as well but was not as
prominent (Figure S1). This relationship did not hold between the
herpes- and polyoma-viruses, i.e. there was no significant
relationship between the load of any of the herpesviruses and
prevalence of either polyomavirus, and vice versa (data not
shown).
Time course of viral detection
During sepsis, virus detection rate increased for all viruses with
ICU duration (Figure 3). The rapidity at which septic patients who
were virus negative at study entry and who converted to virus
positive status during their illness differed for various viruses
(Figure 3B). The fastest conversion rate occurred for TTV with
50% and 75% detection rates occurring at days 3 and 6 after sepsis
onset respectively. Among herpes viruses, the most rapid increase
in detection rate (conversion from negative to positive viremia)
occurred for EBV with 50% and 75% detection rates of 5 and 7
days respectively. CMV had the slowest rise with 50% and 75%
detection rates occurring at days 8 and 13 respectively. The 50%
and 75% conversion rates for HSV were 7 and 10 days
respectively while those for HHV-6 were 7 and 11 days
respectively. Time course for detection of urine BK and JC virus
is depicted in Figure S2.
Correlation of viremia with clinical and laboratory
parameters
Secondary infections. Impaired immunity in septic patients
is frequently manifest by infections with fungal or relatively non-
virulent ‘‘opportunistic’’ type bacterial organisms [40,41]. We
prospectively selected Acinetobacter, Stenotrophomonas, and Enterococcus
as representative of ‘‘opportunistic’’ bacteria in patients with
sepsis; these relatively weakly virulent pathogens are common
causes of secondary infection in our ICUs [41]. Septic patients
who had detectable CMV in either blood or plasma and septic
patients who had EBV detectable in plasma had increased risk of
fungal infections independent of length-of-stay or duration of
sepsis, Figure 4 and Figure S3; (p,0.001 for CMV and p,0.05 for
EBV). For both viruses, the relationship was stronger for detection
of virus in plasma than whole blood. These relationships with
fungal infection were not present for the other viruses examined.
Patients who had detectable HSV in blood had increased risk of
developing opportunistic bacterial infections which was indepen-
dent of length-of-stay, Figure 4, (p,0.05). A similar trend was also
apparent for detection of HSV in plasma but not for any other
virus.
ICU duration and severity of illness. Average ICU length-
of-stay was increased in septic viremic versus non-viremic patients,
Figure 5. Patient microbiologic data and white blood cell counts
are shown in Table 5. For CMV and HSV, the number of ICU
days was approximately doubled in patients who were viral
positive versus viral negative. No effect of urine BK or JC was
observed on length-of-stay. Septic patients with CMV viremia in
blood had increased APACHE-II scores compared to CMV
negative Table 6, p,0.01. Viremia with CMV, EBV, HSV, and
HHV-6 was associated with higher SOFA scores, Table 6, p,
0.01.
Effect of viral reactivation on mortality in sepsis. Septic
patients with detectable CMV in plasma had increased 90-day
mortality compared to CMV negative patients, Figure 6; p#0.05.
The increased mortality with CMV had a stepwise increase in
mortality with increased viral levels, Figure 7; though this was not
statistically significant. Compared to septic patients who were
TTV negative, there was a trend for increased mortality in septic
patients who had the highest quartile of TTV viral load, Figure 7.
Surprisingly, septic patients who were EBV positive in blood (but
not plasma) had lower 90-day mortality, Figure 6; p,0.05. The
protective effect of EBV tended to lessen as viral load increased in
whole blood, Figure 8.
Discussion
A remarkable finding in the present study is the high prevalence
of viral DNA in blood of septic patients. Previous studies which
investigated viral reactivation in sepsis were generally focused on
CMV or, much less commonly, HSV [15,20,24–28,42–44]. This is
the first study to examine the impact of sepsis on multiple families
of viruses. Detection of herpes viruses (CMV, EBV, HSV-1, and
HHV-6), polyomaviruses (JC and BK), and anellovirus (TTV)
occurred with high frequency in sepsis (Tables 2–4). These
increased rates of viral detection are particularly striking when
Figure 3. Peak viral detection rate and time course of viral
detection. The percentage of patients who tested positive in blood for
particular viruses during the course of sepsis (limited to 30 days) is
displayed in two formats. Day 0 represents the day that the patient
fulfilled sepsis criteria [32]. Figure 3A represents all septic patients
positive for viral reactivation divided by the total number of septic
patients who were tested on or before the same day. Figure 3B
represents only those septic patients who were negative for the
particular viruses and who ultimately became positive during their
septic course. The % represents the increase in the number of septic
patients who convert from virus negative to virus positive status. *TTV
was tested only in plasma (see Methods S1).
doi:10.1371/journal.pone.0098819.g003
Viral Reactivation in Sepsis
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Figure 4. Impact of viral reactivation on fungal and opportunistic bacterial infections. Septic patients with CMV detected in either blood
or plasma had increased fungal infections compared to CMV negative patients; only results for plasma are shown and are significant, p,0.001.
Similarly, patients who had EBV detected in blood had increased fungal infections compared to viral negative patients, p=0.05. Patients who were
HSV positive in blood had increased opportunistic bacterial infections due to Stenotrophomonas, Acinetobacter, or Enterococcus compared to viral
negative patients, p,0.05. Censored subject (vertical hash marks) represent patients who were either discharged from the ICU or who died without
events. Analysis was performed using all events but plot was truncated at 60 days for clarity. N = 35 patients with fungal infections, n = 86 patients
with Stenotrophomonas, Acinetobacter, or Enterococcus infections.
doi:10.1371/journal.pone.0098819.g004
Viral Reactivation in Sepsis
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compared to results in non-septic patients and healthy-control
patients. The fact that 42.7% of septic patients had viremia with
multiple viruses as well as the magnitude of viral loads (Figure 1)
provides strong evidence that host immunity is impaired in sepsis.
Potential mechanisms of immunosuppression in sepsis include T-
cell exhaustion, apoptotic depletion of CD4 and CD8 T-cells,
myeloid-derived suppressor cells, and increased T-regulatory cells,
all of which might contribute to viral reactivation [4,23,45,46].
Importantly, EBV, CMV, and HHV-6 detection rates for septic
patients in this study are similar to those reported in stem-cell and
organ transplant patients [47–50]. For example, a study of solid
organ transplant recipients reported detection rates in blood of
56.3% for EBV, 13.7% for HHV-6, 12.2% for BK and 4.9% for
JC [47]. Thus, viral detection in septic patients is comparable to
that in transplants patients who are pharmacologically immuno-
suppressed, providing further support that our findings are
indicative of clinically-relevant immunosuppression.
The 24.2% incidence of CMV reactivation in sepsis in the
present study is similar to other sepsis studies [15,24,25,44,51].
Although HSV pneumonitis occurs in sepsis [20,28,52], the
incidence of HSV viremia in sepsis has (to our knowledge) not
been previously reported. One study noted a .50% incidence of
HHV-6A in critically-ill patients but this study was not confined to
septic patients and the high percentage of HHV-6A reactivation
seems incongruous with their other study finding of absence of
CMV reactivation in their same patients [53]. The incidences of
EBV, TTV, JC, and BK have not previously been reported in
septic patients and therefore represent an important independent
contribution to the literature.
Detection of the various viruses in the present study presumably
represents viral reactivation. Almost all adults have been
previously infected with HHV-6 and ,90% of adults have been
previously infected with EBV [16,49]. The seroprevalences for
HSV-1 and HSV-2 are 58% and 17% respectively [54] while
those for JC and BK are ,70–80% and 60–70% respectively
[17,19,55]. Therefore, it is likely that viral detection in the setting
of sepsis is not due to primary infection but rather to viral
reactivation. The precise mechanisms that lead to reactivation of
latent viruses are not completely established, and indeed may
differ between the different viruses. Pro-inflammatory cytokines,
hypoxia, cell injury, and other stress-related mechanisms can
induce viral reactivation and are commonly present in sepsis
[56,57]. Thus, in addition to impaired immune surveillance, the
initial hyper-inflammatory septic phase likely provides the stimulus
which precipitates viral reactivation. However, the persistence and
degree of elevated viral levels suggests that immune function is
insufficient to effectively clear the viruses, strongly suggesting
immune dysfunction. Most viruses were detected at high levels in
plasma as well as blood (Table 2) and this finding is considered
indicative of active viral replication [58]. Thus, while stress-
induced mechanisms might initiate viral reactivation in sepsis, the
predominant driving force for the extent, persistence, and degree
of viral reactivation in most septic patients is most likely to be
immune dysfunction. The degree and magnitude of viral loads is
also consistent with impaired immunity in septic patients (see
discussion below for EBV and TTV viral loads and immunosup-
pression).
EBV blood level is used as a surrogate marker of immunosup-
pression in transplant patients [49,59,60]. Fifty-two septic patients
had EBV levels $10,000 copies/ml of whole blood, a level that
some transplant clinicians consider to represent excessive immu-
nosuppression and therefore advise reduction in anti-rejection
medications [60]. Previous studies have also shown correlation
between circulating TTV levels and immunocompetence [29–
31,61]. Unlike herpes viruses, TTV is not thought to enter latency
Figure 5. Patients with viral reactivation have increased ICU
length of stays. The average number of days spent in the ICU for
septic patients with versus without viremia was determined. Septic
patients who were positive for CVM, EBV, TTV, HSV, and HHV-6 had
longer ICU stays compared to comparable patients who were viral
negative. There was no impact of urine JC or BK positivity on ICU length
of stay. Values were compared by student’s t test.
doi:10.1371/journal.pone.0098819.g005
Table 5. Microbiology and Blood Cell Counts.
Septic Critically-ill Non-septic Healthy Controls
Microbiology Gram Negative 389
Gram Positive 323
Fungae 39
White blood cell count (K/mm3) median 13.1 8.1 6.4
range (IQR) 10.3–18.9 6.7–9.2 5.5–7.7
Absolute Lymphocytes K/mm3 median 0.9 1.1 1.8
range (IQR) 0.6–1.3 0.7–1.6 1.4–2.3
Absolute Monocytes K/mm3 median 0.7 0.6 0.5
range (IQR) 0.4–1.1 0.4–0.8 0.4–0.6
Absolute Polymorphonuclear K/mm3 median 11.8 6 4.1
range (IQR) 8.5–16.7 5.0–7.4 3.2–5.5
doi:10.1371/journal.pone.0098819.t005
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but rather to actively replicate at low levels and is present in
plasma in ,50% of healthy adults without known pathologic
effects [29–33]. Previous studies reported that elevated TTV viral
loads occur more frequently in hemodialysis patients, diabetics,
and HIV-infected patients with low CD4 counts than in healthy
individuals or HIV-infected patients with CD4 counts .500/mm3
[29–33]. Three studies have reported that TTV viremia increases
with the degree of immunosuppressive therapy in patients with
organ transplantation and suggested that the magnitude of TTV
viremia is indicative of the robustness of the immune system [31–
33]. The high prevalence (76.4%) and viral load of TTV in septic
patients likely reflects their immunosuppression.
A critical question which is not answered by the present study is
whether the increased viral reactivation in sepsis is merely a
marker of impaired immunity or contributes to sepsis morbidity/
mortality. A subgroup of septic patients had extremely high levels
of CMV and/or EBV (Figure 1) which are frequently associated
with pathological effects. A current hypothesis is that CMV and
HSV reactivation amplify sepsis-induced lung and systemic
inflammation thereby contributing to multi-organ failure
[15,61,62]. Additionally, chronic viral infections lead to T cell
exhaustion and impaired immunity [63], and a recent postmortem
study of septic patients demonstrated findings highly consistent
with T cell exhaustion [23]. Thus, viral reactivation in sepsis could
lead to T cell exhaustion which further impairs host immunity
leading to additional viral reactivation. Septic patients who had
viral reactivation had increased infections with organisms that
generally do not infect patients with competent immune systems,
e.g. Candida albicans, Stenotrophomonas, Acinetobacter, Enterococcus
(Figure 4) [40,41]. While this commensal fungus and these
bacteria are generally considered opportunistic bacteria, they
may enter the bloodstream through barrier breakdown. Whether
the increased propensity for infections with relatively weakly
pathogenic organisms is a result of viral-mediated effects to impair
immunity or whether viral reactivation occurs more readily in
more profoundly immunosuppressed septic patients is unknown.
A surprising finding is the decreased mortality in septic patients
with EBV viremia in blood (but not plasma) compared to EBV-
negative patients (Figure 6). A potential explanation for this
seemingly paradoxical finding is provided by studies showing that
mice with low level gammaherpes-virus-68 infection (a murine
virus genetically similar to human EBV) have improved survival
and/or decreased microbial burden in bacterial sepsis due to L.
monocytogenes and Y. pestis [64]. In that animal model, EBV infection
protected by activating NK cells to produce IFN-c, an essential
factor for viral control. Significantly, EBV in plasma did not
display a survival benefit and was associated with increased fungal
infections. These findings may signal a fundamental difference
Table 6. Correlation of Viral Positivity and Severity of Illness.
Mean{ APACHE II (S.E.M.) Mean{ SOFA (S.E.M.)
Virus Virus Positive Virus Negative P-value Virus Positive Virus Negative P-value
CMV* 18.2 (0.58) 16.3 (0.39) 0.002 9.5 (0.41) 8.3 (0.20) ,0.01
EBV 17.2 (0.26) 17.4 (0.33) 0.687 8.9 (0.20) 8.0 (0.20) ,0.01
HSV 17.4 (0.49) 17.3 (0.23) 0.346 9.8 (0.42) 8.3 (0.15) ,0.001
HHV-6 18.4 (0.77) 17.2 (0.22) 0.145 9.8 (0.42) 8.3 (0.14) ,0.001
TTV 16.7 (0.26) 15.9 (0.44) 0.94 8.5 (0.19) 8.2 (0.26) 0.264
JC 16.3 (0.49) 16.6 (0.44) 0.783 7.3 (0.35) 7.4 (0.28) 0.963
BK 15.4 (0.60) 16.6 (0.37) 0.247 7.2 (0.48) 7.4 (0.24) 0.897
{Mean value represents mean of all patients’ average APACHE II or SOFA score for the duration of their ICU stay.
*Represents CMV seropositive patients only.
doi:10.1371/journal.pone.0098819.t006
Figure 6. Impact of CMV and EBV on sepsis mortality. Septic patients who were CMV positive in plasma had increased 90 day mortality
compared to CMV negative patients, p,0.05. Surprisingly, patients who were EBV positive in whole blood (but not plasma) had decreased 90 day
mortality compared to EBV negative patients, p,0.001. Data analyzed by Kaplan Meier.
doi:10.1371/journal.pone.0098819.g006
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between patients with low and high levels of EBV in blood. We
speculate that early reactivation of EBV in sepsis identifies patients
who mount a more vigorous response to the pathogens. However,
persistent EBV at high levels is likely detrimental to the host.
There are several significant implications of the present study.
First, the current results highlight a degree of immunosuppression
in septic patient that is on par with pharmacologically-induced
immunosuppression in organ transplant patients [47–50]. Sec-
ondly, an intriguing idea is that serial quantitation of circulating
viral load for a panel of viruses may be useful as a biomarker of
host immunity in sepsis. This concept of tracking changes in viral
load is similar to the approach used to guide dosing of
immunosuppressive mediations in some organ transplant recipi-
ents [47–50]. Besides the viruses quantitated in the present study,
HHV-7, adenovirus, parvovirus B19, and human bocavirus are
other candidates that might provide additional information
regarding the status of host immunity [64,65,66]. Finally, these
results provide a strong rationale for future and ongoing clinical
trials of agents that boost host immunity in patients who have
entered the immunosuppressive phase of sepsis [11,12].
A limitation to this study is the inability to make direct
comparisons between septic and control groups. The ICU length-
of-stay for CINS was considerably shorter than for septic patients
because these patients tended to be more clinically stable and were
transferred out of the ICU. Consequently, more serial-samples
were obtained from septic versus CINS patients, undoubtedly
contributing to the increased detection of viral DNA in sepsis.
Additionally, severity of illness in septic patients is invariably
higher as a consequence of sepsis-induced multi-organ dysfunc-
tion. These issues make direct statistical comparisons between
septic and control patients invalid. However, 31 CINS patients
who became septic during their ICU stay were included and these
patients had viral reactivation typical of the septic group at large
following sepsis onset. It is possible that viral reactivation may not
be related simply to sepsis but could extend to all critically-ill
patients with similar severity of illness and length-of-stay. In this
regard, EBV reactivation was higher in CINS patients versus
healthy controls, p,0.003.
Conclusions
In conclusion, reactivation of latent viruses is extremely
common in patients with prolonged sepsis and is consistent with
development of immunosuppression. Whether reactivated viruses
represent an epiphenomenon or contribute to morbidity and
mortality remains unknown and should be addressed because of
Figure 7. Impact of CMV and TTV viral loads on sepsis mortality. The relationship between CMV and TTV viral load in blood and 90 day
mortality is displayed. There was a non-statistically significant increase in mortality due to sepsis with increasing CMV viral levels in blood. (Note that
septic patients who were CMV positive in plasma did have increased mortality compared to CMV negative patients - see Figure 6). Compared to
septic patients who were TTV negative, patients with the highest quartile viral load for TTV (Q4) had a trend toward increased 90 day mortality
(p=0.06).
doi:10.1371/journal.pone.0098819.g007
Figure 8. Effect of EBV load on survival. EBV in whole blood (but not plasma) was associated with a decrease in sepsis mortality. This protective
effect of EBV DNAemia tended to lessen with increased viral burden although the effect was not statistically significant.
doi:10.1371/journal.pone.0098819.g008
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their potential impact on morbidity and mortality. Serially
tracking of viral load for a panel of latent viruses might be useful
as indicators of the state of host immunity.
Supporting Information
Figure S1 Effect of viral load on prevalence of other
viruses. This Figure corresponds to Figure 2 displaying results for
plasma as opposed to blood. Populations were established based
upon viral DNA loads; each of these populations was examined for
presence or absence of other viruses. Groups are defined as
Negative = no detectable virus; Low= less than the median DNA
load; High= greater than or equal to median DNA load. Negative,
low, and high values for CMV (median= 3,243, n= 115, 16, 17
respectively) and HSV (median= 10,640, n = 193, 21, 21 respec-
tively). For EBV and HHV-6, Negative = no detectable virus
(n = 146 and n= 205 respectively), Positive = detectable virus
(n = 72 and n=30 respectively). For TTV, Negative = no
detectable virus (n = 52), Q1= first quartile (,5,881 copies/mL
n=45), Q2= second quartile (between 5,881 and 33,504 copies/
mL, n= 45), Q3= third quartile (between 33,717 and 299,609
copies/mL, n= 45), and Q4= fourth quartile (.299,609 copies/
mL, n= 44). Although the correlation is not as striking as in blood
(Figure 2), there is a correlation between the viruses such that as
the level of one virus increases, there tends to be a concomitant
increase in the prevalence of other herpes viruses.
(TIF)
Figure S2 Peak detection rate and time course of
detection for BK and JC. The percentage of patients who
tested positive in urine JC or BK virus during the course of sepsis
(limited to 30 days) is displayed in two formats. Day 0 represents
the day that the patient fulfilled sepsis criteria. Figure S2A.
represents all septic patients positive for viral reactivation divided
by the total number of septic patients who were tested on or before
the same day. The plot starts at day 3 because of skewing of
display by small patient numbers. Figure S2B represents only those
septic patients who were negative for the particular viruses and
who ultimately became positive during their septic course. The %
represents the increase in the number of septic patients who
convert from virus negative to virus positive status.
(TIF)
Figure S3 Percentage of fungal infections in septic
patients. The percentage of hospital-acquired fungal infections
at day 60 were quantitated for septic patients with or without
CMV and EBV viral reactivation. Note that patients whose blood
was positive for CMV or EBV had increased incidence of fungal
infections as depicted in the vertical axis. (The data for the
relationship between fungal and opportunistic bacterial infections
for patients who were positive for CMV or EBV in plasma is
shown in Figure. 4. Censored subject (vertical hash marks)
represent patients who were either discharged from the ICU or
who died without events. Analysis was performed using all events
but plot was truncated at 60 days for clarity.
(TIF)
Table S1 qPCR assays. Characteristics of virus qPCR assays,
including LLOQs (Lower Limits of Quantitation), average CVs
and references.
(CSV)
Methods S1 Supporting materials and methods. Expands
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